Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation

Blockade of costimulation and adhesion signaling is an attractive approach to interfere with graft rejection Between January 1997 and May 1999, forty adults having benign liver diseases were included in a prospective, randomized study comparing tacrolimus plus low-dose short-term steroids without (n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation 2005-11, Vol.80 (9), p.1186-1193
Hauptverfasser:	LERUT, Jan, VAN THUYNE, Vincent, GIANELLO, Pierre, BAZIN, Hervé, CORNET, Anne, RAHIER, Jacques, LATINNE, Dominique, MATHIJS, Jules, LEMAIRE, Julien, TALPE, Stéphanie, ROGGEN, Francine, CICCARELLI, Olga, ZUCKERMANN, Michele, GOFFETTE, Pierre, HOPE, James
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Biological and medical sciences CD2 Antigens - immunology Dose-Response Relationship, Drug Drug Administration Schedule Fundamental and applied biological sciences. Psychology Fundamental immunology Graft Rejection - epidemiology Graft Survival Humans Immunosuppressive Agents - therapeutic use Incidence Infection - complications Liver Failure - complications Liver Failure - surgery Liver Transplantation - immunology Lymphocyte Count Medical sciences Middle Aged Neoplasms - complications Postoperative Period Steroids - administration & dosage Steroids - therapeutic use Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Survival Analysis Tacrolimus - therapeutic use Tissue, organ and graft immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Blockade of costimulation and adhesion signaling is an attractive approach to interfere with graft rejection Between January 1997 and May 1999, forty adults having benign liver diseases were included in a prospective, randomized study comparing tacrolimus plus low-dose short-term steroids without (n=20, TAC group) or with a 10-day course of antihuman CD2 monoclonal antibody (n=20, BTI group). At day 7, histological rejection expressed by mean Banff scores (2.3+/-1.6 vs. 5.4+/-1.6 in the TAC group; Por=6) (0 vs. 10 [50%] in the TAC group; P
ISSN:	0041-1337 1534-6080
DOI:	10.1097/01.TP.0000173996.81192.F9